IP
GILD icon

Intellectus Partners’s Gilead Sciences GILD Stock Holding History

Intellectus Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$46.5K – 261
2022
Q4 		$46.5K Buy
+10,000
New +$792K 0.02% 250

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Intellectus Partners's GILD Position: Q2 2026 in Review

Intellectus Partners held its Gilead Sciences (GILD) position steady in Q2 2026 at 8,947 shares worth $1.13M. The position accounts for 0.2% of the portfolio, ranked #128.

Intellectus Partners first reported a position in GILD in Q4 2016 and has held it in 39 quarters since. The position peaked at $4.74M in Q4 2018. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Intellectus Partners held 8,947 shares of Gilead Sciences worth $1.13M as of Q2 2026.
  • Intellectus Partners left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.2% of Intellectus Partners's portfolio in Q2 2026, its #128 holding.
  • Intellectus Partners first reported a position in Gilead Sciences in Q4 2016 and has held it in 39 quarters since.
  • Intellectus Partners's Gilead Sciences position peaked at $4.74M in Q4 2018.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.